Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COMMENTARY
COMMENTARY
- Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
- Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
- Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
- Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
- Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
- Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
- Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
- Era of Competition Dawns in Market for AD Treatments
June 27, 2011
- Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
- Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
- Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
- GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
- Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
- Japan's Most Admired Pharma Companies in 2010
April 4, 2011
- Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
- Use of Generics by Welfare Recipients
March 7, 2011
- Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
- Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
- Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
- Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…